Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia
Introduction
Historically, the taxonomy of Stenotrophomonas maltophilia has evolved from previous genus classifications as Pseudomonas and Xanthomonas (Denton & Kerr, 1998). Theories regarding the organism's route of acquisition and virulence have been equally controversial. Over the past decade, however, S. maltophilia has emerged as an important nosocomial pathogen (Calza et al, 2003, Denton & Kerr, 1998) with patient morbidity and mortality similar to that observed with other Gram-negative infections (Hanes et al, 2002, Morrison et al, 1986, Senol et al, 2002). S. maltophilia infections including pneumonia, bacteremia, and urinary tract are associated with intensive care unit admission, mechanical ventilation, central venous catheterization, immunosuppression, and broad-spectrum antibiotic therapy (Denton & Kerr, 1998).
With few clinical studies and limited knowledge related to antibiotic pharmacodynamics against S. maltophilia, the management of clinical infection relies largely on minimum inhibitory concentrations (MIC) testing. Antibiotic selection is further complicated by high rates of resistance to antibiotics including β-lactams (eg, piperacillin–tazobactam, 40%; ceftazidime, 40%), fluoroquinolones (eg, ciprofloxacin, 53%), and aminoglycosides (eg, tobramycin, 81%) (Gales et al, 2001). In clinical practice, trimethoprim–sulfamethoxazole (TMP–SMX), which demonstrates relatively low rates of resistance (ie, <5%), has become a common treatment of choice. Notably, several recent studies have demonstrated the importance of appropriate antibiotic selection on patient outcome, including survival (Friedman et al, 2002, Hanes et al, 2002, Senol et al, 2002). As one author suggested “patients do not die as a result of S. maltophilia pneumonia but, rather, as a result of the lack of adequate empiric antibiotic therapy” (Hanes et al, 2002).
The goal of this study was to investigate clinical doses of TMP–SMX alone and in combination against S. maltophilia in an in vitro pharmacodynamic model (IPDM). The intention was to generate data to assist therapeutic decisions in the management of serious S. maltophilia infections.
Section snippets
Isolates, antibiotics, and media
Clinical S. maltophilia isolates were identified using a microbiology laboratory database (Microscan®, Dade Diagnostics, Mississauga, ON) of records between 2000 and 2002. Four isolates associated with clinical infection were selected including a peritoneal fluid isolate from a dialysis outpatient in October 2001 (isolate 828), a blood isolate from a hemodialysis outpatient in September 2001 (isolate 503), an endobronchial fluid isolate from a medical intensive care patient in May 2002 (isolate
Results
In static kill curve studies, only ceftazidime alone against isolate 229 produced bacterial kill at 24 h compared with the initial inocula. However, all antibiotic combinations produced net bacterial kill including TMP–SMX plus ceftazidime against isolate 828, TMP–SMX plus ciprofloxacin against isolate 503, TMP–SMX plus gentamicin against isolate 233, and TMP–SMX plus ceftazidime, TMP–SMX plus ciprofloxacin, TMP–SMX plus tobramycin, ceftazidime plus ciprofloxacin, ceftazidime plus tobramycin,
Discussion
There is mounting evidence that clinical outcome is critically dependent on antibiotic selection in the management of S. maltophilia infection. Recent studies have reported significantly lower death rates in patients with bloodstream (Friedman et al, 2002, Senol et al, 2002) and respiratory tract infections (Hanes et al, 2002) treated with appropriate antibiotic therapy. Unfortunately, the challenge of antibiotic selection in clinical practice relies largely on MICs, observational studies, and
References (21)
- et al.
Bacteraemia due to Stenotrophomonas maltophilia: An analysis of 45 episodes
J. Infect.
(2002) - et al.
Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia
Diagn. Microbiol. Infect. Dis.
(2002) - et al.
In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia
Diagn. Microbiol. Infect. Dis.
(1999) - et al.
Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic–pharmacodynamic model
Antimicrob. Agents Chemother.
(2004) In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives
J. Antimicrob. Chemother.
(1985)- et al.
Stenotrophomonas (Xanthomonas) maltophilia as an emerging opportunistic pathogen in association with HIV infection: A 10-year surveillance study
Infection
(2003) - et al.
In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms
J. Antimicrob. Chemother.
(2003) - et al.
Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia
Clin. Microbiol. Rev.
(1998) - et al.
Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: Geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997–1999)
Clin. Infect. Dis.
(2001) - et al.
Stenotrophomonas maltophilia: Emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model
Antimicrob. Agents Chemother.
(1996)
Cited by (73)
Appropriate antibiotic therapy is a predictor of outcome in patients with Stenotrophomonas maltophilia blood stream infection in the intensive care unit
2023, Journal of Microbiology, Immunology and InfectionFluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis
2019, Clinical Microbiology and InfectionEarly prosthetic endocarditis caused by Stenotrophomonas maltophilia
2018, Medecine et Maladies InfectieusesCitation Excerpt :Their authors thus recommended the use of TMP-SMX in combination with other antibiotics (two or three) for the treatment of severe S. maltophilia infection (sepsis, immunodeficiency, and endovascular infections). Furthermore, antimicrobials must be used at the maximum tolerated dose [9]. Other antibiotic options are [8]:
Stenotrophomonas maltophilia: From trivial to grievous
2017, Indian Journal of Medical MicrobiologyLong Story Short: Establishing Breakpoints for Antimicrobials and 2023 Updates
2024, Current Infectious Disease ReportsStenotrophomonas maltophilia: An Urgent Threat with Increasing Antibiotic Resistance
2024, Current Microbiology